{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T15:11:38Z","timestamp":1721056298204},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Assiciazione Italiana Ricerca sul Cancro","award":["IG 15373, 2014"],"award-info":[{"award-number":["IG 15373, 2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00262-018-2191-3","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:24:56Z","timestamp":1529972696000},"page":"1317-1324","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge"],"prefix":"10.1007","volume":"67","author":[{"given":"Luana","family":"Calabr\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"2191_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/BLT.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89:716\u2013724","journal-title":"Bull World Health Organ"},{"issue":"5 suppl","key":"2191_CR2","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S (2015) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(5 suppl):v31\u20139","journal-title":"Ann Oncol"},{"key":"2191_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"issue":"10026","key":"2191_CR4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier R, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivi\u00e8r F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT) (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387(10026):1405\u20131414","journal-title":"Lancet"},{"issue":"4","key":"2191_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","volume":"16","author":"LM Krug","year":"2015","unstructured":"Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, \u00d6hman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P (2015) Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16(4):447\u2013456","journal-title":"Lancet Oncol"},{"issue":"17","key":"2191_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974\u20131982","journal-title":"J Clin Oncol"},{"issue":"7","key":"2191_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/imt-2016-0002","volume":"8","author":"C Kyi","year":"2016","unstructured":"Kyi C, Postow MA (2016) Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy 8(7):821\u2013837","journal-title":"Immunotherapy"},{"issue":"5","key":"2191_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.seminoncol.2010.09.006","volume":"37","author":"L Calabr\u00f2","year":"2010","unstructured":"Calabr\u00f2 L, Danielli R, Sigalotti L, Maio M (2010) Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 37(5):460\u2013467","journal-title":"Semin Oncol"},{"issue":"10","key":"2191_CR9","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33(10):1191\u20131196","journal-title":"J Clin Oncol"},{"issue":"11","key":"2191_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","volume":"60","author":"AJ Bograd","year":"2011","unstructured":"Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS (2011) Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 60(11):1509\u20131527","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"2191_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/imt.12.108","volume":"4","author":"R Cornelissen","year":"2012","unstructured":"Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG (2012) Immunotherapy 4(10):1011\u20131022","journal-title":"Immunotherapy"},{"key":"2191_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","volume":"14","author":"L Calabr\u00f2","year":"2013","unstructured":"Calabr\u00f2 L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:1104\u20131111","journal-title":"Lancet Oncol"},{"issue":"1","key":"2191_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00262-014-1609-9","volume":"64","author":"L Calabr\u00f2","year":"2015","unstructured":"Calabr\u00f2 L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M (2015) CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic\/target therapy? Cancer Immunol Immunother 64(1):105\u2013112","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2191_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","volume":"3","author":"L Calabr\u00f2","year":"2015","unstructured":"Calabr\u00f2 L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 3(4):301\u2013309","journal-title":"Lancet Respir Med"},{"issue":"9","key":"2191_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabr\u00f2 L, Aerts J, Perez CS, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Atonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicenter, international, randomized, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18(9):1261\u20131273","journal-title":"Lancet Oncol"},{"key":"2191_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407\u2013416","journal-title":"Nat Genet"},{"issue":"5","key":"2191_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66(5):551\u2013564","journal-title":"Cancer Immunol Immunother"},{"key":"2191_CR18","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA (2016) Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 375:1767\u20131778","journal-title":"N Engl J Med"},{"key":"2191_CR19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","volume":"4","author":"MM Awad","year":"2016","unstructured":"Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, Richards WG, Barbie DA, Bass AJ, Rodig SJ, Hodi FS, Wucherpfennig KW, J\u00e4nne PA, Sholl LM, Hammerman PS, Wong KK, Bueno R (2016) Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors. Cancer Immunol Res 4:1038\u20131048","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2191_CR20","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E (2015) Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One 10(3):e0121071","journal-title":"PLoS One"},{"key":"2191_CR21","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","volume":"11","author":"S Khanna","year":"2016","unstructured":"Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R (2016) Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol 11:1993\u20132005","journal-title":"J Thorac Oncol"},{"key":"2191_CR22","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"AS Mansfield","year":"2014","unstructured":"Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED (2014) B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9:1036\u20131040","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2191_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18(5):623\u2013630","journal-title":"Lancet Oncol"},{"key":"2191_CR24","doi-asserted-by":"crossref","unstructured":"Quispel-Janssen J, Zago J, Schouten R et al (2017) A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies. J Thorac Oncol 12,(suppl abstr 13.0, presented at the World Conference on Lung Cancer 2016)","DOI":"10.1016\/j.jtho.2016.11.300"},{"issue":"3","key":"2191_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1164\/rccm.201608-1755CI","volume":"196","author":"LA Lievense","year":"2017","unstructured":"Lievense LA, Sterman DH, Cornelissen R, Aerts JG (2017) Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med 196(3):274\u2013282","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2191_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","volume":"194","author":"R Das","year":"2015","unstructured":"Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM (2015) Combination therapy with anti-CTLA4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194(3):950\u2013959","journal-title":"J Immunol"},{"issue":"13","key":"2191_CR27","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373(13):1270\u20131271","journal-title":"N Engl J Med"},{"key":"2191_CR28","doi-asserted-by":"crossref","unstructured":"Calabr\u00f2 L, Morra A, Giannarelli D, Amato G, Bertocci E, D\u2019Incecco A, Danielli R, Brilli L, Giannini F, Altomonte M, Di Giacomo AM, Maio M (2017) Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study. J Clin Oncol 35 (suppl; abstr 8558, presented at the American Society of Clinical Oncology (ASCO) 2017)","DOI":"10.1200\/JCO.2017.35.15_suppl.8558"},{"key":"2191_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30151-6","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Morra A, Giannarelli D, Amato G, D\u2019Incecco A, Danielli R, Alessia Covre A, Lewis MC, Altomonte M, Di Giacomo AM, Maio M (2018) Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: the exploratory, non-randomised, phase 2, NIBIT-MESO-1 study. Lancet Resp Med. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(18)30151-6","journal-title":"Lancet Resp Med"},{"key":"2191_CR30","doi-asserted-by":"crossref","unstructured":"Scherpereel A, Mazieres J, Greillier L, D\u00f4 P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Thiberville L, Urban T, Ligeza-poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G (2017) Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol 35(suppl; abstr LBA8507, presented at the American Society of Clinical Oncology (ASCO) 2017)","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507"},{"issue":"1","key":"2191_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207\u2013214","journal-title":"Cancer"},{"issue":"2","key":"2191_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15(2):257\u2013260","journal-title":"Ann Oncol"},{"issue":"1","key":"2191_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/09031936.00146110","volume":"38","author":"T Frauenfelder","year":"2011","unstructured":"Frauenfelder T, Tutic M, Weder W, Gotti RP, Stahel RA, Seifert B, Opitz I (2011) Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma. Eur Respir J 38(1):162\u2013168","journal-title":"Eur Respir J"},{"issue":"23","key":"2191_CR34","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412\u20137420","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2191_CR35","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1158\/1078-0432.CCR-14-3128","volume":"21","author":"A Hoos","year":"2015","unstructured":"Hoos A, Wolchok JD, Humphrey RW, Hodi FS (2015) CCR 20th anniversary commentary: immune-related response criteria-capturing clinical activity in immuno-oncology. Clin Cancer Res 21(22):4989\u20134991","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2191_CR36","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143\u2013e152. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"issue":"7","key":"2191_CR37","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.ejrad.2014.03.019","volume":"83","author":"DP Noij","year":"2014","unstructured":"Noij DP, Boerhout EJ, Pieters-van den Bos IC, Comans EF, Oprea-Lager D, Reinhard R, Hoekstra OS, de Bree R, de Graaf P, Castelijns JA (2014) Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study. Eur J Radiol 83(7):1144\u20131151","journal-title":"Eur J Radiol"},{"issue":"11","key":"2191_CR38","doi-asserted-by":"publisher","first-page":"e109866","DOI":"10.1371\/journal.pone.0109866","volume":"9","author":"K Higashikawa","year":"2014","unstructured":"Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, Enomoto S (2014) 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One 9(11):e109866","journal-title":"PLoS One"},{"issue":"10","key":"2191_CR39","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.7150\/thno.15253","volume":"6","author":"M Hettich","year":"2016","unstructured":"Hettich M, Braun F, Bartholom\u00e4 MD, Schirmbeck R, Niedermann G (2016) High-resolution PET imaging with therapeutic antibody-based PD-1\/PD-L1 checkpoint tracers. Theranostics 6(10):1629\u20131640","journal-title":"Theranostics"},{"issue":"10","key":"2191_CR40","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2967\/jnumed.116.173930","volume":"57","author":"BM Larimer","year":"2016","unstructured":"Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U (2016) Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy. J Nucl Med 57(10):1607\u20131611","journal-title":"J Nucl Med"},{"issue":"2","key":"2191_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4329\/wjr.v9.i2.27","volume":"9","author":"M Bauckneht","year":"2017","unstructured":"Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S (2017) Evaluation of response to immune checkpoint inhibitors: is there a role for positron emission tomography? World J Radiol 9(2):27\u201333","journal-title":"World J Radiol"},{"key":"2191_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:98\u2013106","journal-title":"Am J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2191-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T19:13:38Z","timestamp":1561490018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2191-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2191"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2191-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"7 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Luana Calabr\u00f2 served on the advisory board of Bristol Myers Squibb; Aldo Morra declares no conflict of interest; Robin Cornelissen served on advisory boards of Boehringer-Ingelheim, Roche, and Lilly; Joachim Aerts served on advisory boards of Eli-Lilly Bristol Myers Squibb, Roche-Genetech, Astra-Zeneca, MSD Sharp & Dohme, and Boehringer Ingelheim, and is a stock owner of Amphera Immunotherapy; Michele Maio served on advisory boards of Bristol Myers Squibb, Roche-Genentech, and AstraZeneca-MedImmune.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We obtained oral consent from the three patients (reported in the clinical cases) for the description and publication of their cases (including figures).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}}]}}